Belimumab: A BLyS-specific inhibitor for systemic lupus erythematosus

Annals of Pharmacotherapy

Volumn 44, Issue 12, 2010, Pages 1955-1961

  Wiglesworth, Amy K ^a   Ennis, Kelly M ^b   Kockler, Denise R ^b,c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

B lymphocyte stimulators; Belimumab; Benlysta; BLyS specific inhibitors; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; BENLYSTA; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG;

ARTHRALGIA; B LYMPHOCYTE; CLINICAL TRIAL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; INFLUENZA; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUGS, INVESTIGATIONAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 78649955057     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P360     Document Type: Review

References (37)

1. Lupus Foundation of America. Statistics on lupus. http://www.lupus.org/ webmodules/webarticlesnet/templates/new-newsroomreporters.aspx?articleid= 247&zoneid=60 (accessed 2010 Aug 2).
2. Lawrence RC, Felson DT, Helmick CG, et al., for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008; 58:26-35.
3. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005;19:658-708.
4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 1997;40:1725.
5. Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis 1955;1:12-32.
6. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus: results from a single center. II. Predictor variables for mortality. J Rheumatol 1995;22:1265-70.
7. Human Genome Sciences and GlaxoSmithKline announce FDA priority review designation for Benlysta (belimumab) as a potential treatment for systemic lupus erythematosus. http://www.hgsi.com/belimumab.html (accessed 2010 Aug 20).
8. Health News Daily. Belimumab shows efficacy for lupus in second pivotal trial. http://healthnewsdaily.elsevierbi.com/cs/Satellite?c=Page&cid= 1216099165884 (accessed 2010 Apr 10).
9. Davis J. GlaxoSmithKline's Whitty plays down impact of US health care reform. The Pink Sheet. May 3, 2010.
10. Regulatory update-BLA filed for belimumab (Benlysta) http://www. gsk.com/media/pressreleases/2010/2010-pressrelease-10052.htm (accessed 2010 Jul 30).
11. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to b-lymphocyte stimulator. Drugs R D 2008;9:197-202.
12. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003;56:481-90.
13. Crispin JC, Liossis S-NC, Kis-Toth K, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Molec Med 2010; 16:47-57.
14. Isenberg DA, Shoenfeld Y, Walport M, et al. Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum 1985;28:999-1007.
15. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39.
16. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285:260-3.
17. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BlyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109. DOI 10.1186/ar2606
18. Brady JR, Chan B, Lee WP, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 2001;11:1547-52.
19. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulation enhancement of humoral immune response. J Exp Med 2000;102:953-64.
20. Zhang J, Roschke V, Baker KP, et al. Role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10.
21. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-9.
22. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator over-expression in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:3475-86.
23. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253-65.
24. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685-91.
25. Bruce IN, Gordon C, Merrill JT, Isenberg D. Clinical trials in lupus: what have we learned so far? Rheumatology 2010;49:1025-7.
26. Isenberg DA, Gordon C. From BILAG to BLIPS - disease activity assessment in lupus past, present, and future. Lupus 2000;9:1961-2033.
27. Wallace DJ, Stohl W, Furie RA, Lisse JR. A phase II, randomized, double- blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61:1168-78.
28. Jacobi AM, Huang W, Wang T. Effect of long term belimumab treatment on B cells in systemic lupus erythematosus. Arthritis Rheum 2010;62: 201-10.
29. GlaxoSmithKline and Human Genome Sciences announce topline 76-week results of phase 3 trial of Benlysta in systemic lupus erythematosus, Apr. 20, 2010. www.gsk.com/media/pressreleases/2010/2010-pressrelease-10039. htm (accessed 2010 Apr 20).
30. Human Genome Sciences Inc. and GlaxoSmithKline announce positive phase 3 study results for Benlysta in systemic lupus erythematosus. www.hgsi.com/latest/ human-genome-sciences-and-glaxosmithkline-announce- 2.html (accessed 2010 May 4).
31. Navara S, Guzman R, Gallacher A. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. Presented at: 73rd Annual Scientific Meeting of the American College of Rheumatology. Philadelphia, PA, October 20, 2009.
32. van Vollenhoven RF, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Ann Rheum Dis 2010;69(suppl l3):74.
33. Human Genome Sciences Inc.: Benlysta (belimumab). http://www.hgsi. com/belimumab.html (accessed 2010 Jun 5).
34. Petrie MA, Furie RA, Merrill JT, et al. Four-year experience of belimumab, a BlyS-specific inhibitor, in systemic lupus erythematosus. Presented at: 73rd Annual Scientific Meeting of the American College of Rheumatology. Philadelphia, PA, October 21, 2009.
35. Human Genome Sciences Inc. and GlaxoSmithKline announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus. www.hgsi.com/latest/human-genome-sciences-and-glaxosmithkline-announce- positive-results-in-second-of-two-phase-3-trials-of-benlysta-insystemic- lupus-erythema-6.html (accessed 2010 Jun 4).
36. Lupus Foundation of America. Statistics on Lupus. www.lupus.org/ webmodules/webarticlesnet/templates/new-newsroomreporters.aspx? articleid=247&zoneid=60 (accessed 2010 Apr 1).
37. Market snapshot: after Benlysta breakthrough, how high the sky in lupus? BioPharmaToday. October 13, 2009. www.biopharmatoday.com/2009/ 10 (accessed 2010 May 25).